Celltrion Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
3
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Systems and methods for cryogenic storage (US 11,662,132) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 16, 2027The maintenance fee for Method for separating antibody isoforms using cation exchange chromatography (US 10,351,592) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Stable liquid pharmaceutical preparation (US 11,730,698) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Epitope of hepatitis B virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis B virus (US 10,507,240) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Sep 8, 2027The maintenance fee for Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same (US 9,278,996) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.
- 3 fees due Oct 7 to 12, 2027 · next Oct 7
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,361,790 | Human host cell for producing recombinant proteins with high quality and quantity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,309,519 | Method for selecting a high expression recombinant cell line In force · From the USPTO record | In force | From the USPTO record | |
| US 8,772,021 | Expression vector for animal cell comprising at least one copy of MAR DNA sequences at the 3′ terminal of transcription termination region of a gene and method for the expression of foreign gene using the vector In force · From the USPTO record | In force | From the USPTO record | |
| US 9,834,594 | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses In force · From the USPTO record | In force | From the USPTO record | |
| US 9,024,000 | Method to Improve the Sorbent Efficiency of Protein a Chromatography Using Switching Column with Continuous Feeding In force · High confidence | In force | High confidence | |
| US 9,475,861 | Binding molecule having influenza A virus-neutralizing activity produced from human B cell In force · From the USPTO record | In force | From the USPTO record | |
| US 9,856,312 | Binding molecule having influenza A virus-neutralizing activity produced from human B cell In force · From the USPTO record | In force | From the USPTO record | |
| US 9,573,991 | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses In force · From the USPTO record | In force | From the USPTO record | |
| US 9,278,996 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,610,587 | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 35: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 3 abandoned · 3 no status recorded